Novo Nordisk disputes claims that orforglipron outperforms the Wegovy pill

Novo Nordisk pushed back on comparisons between two oral GLP-1 medicines on April 1, 2026, saying reports that Foundayo (orforglipron) is more effective than the Wegovy pill for weight management are "inaccurate and misleading" ^[1].

The statement came from Jamey Millar, who leads Novo Nordisk's US operations ^[1]. In it, Millar framed the two oral GLP-1 treatments as clinically distinct from each other ^[1].

The Wegovy pill is an oral form of semaglutide. Foundayo is orforglipron. Both are taken by mouth, which distinguishes them from the injectable versions of these medicines that most US patients currently use.

What the statement did not include is as notable as what it did. It cited no weight-loss percentages, no trial names, no patient counts and no study durations ^[1]. It did not identify which reports Millar was responding to, who published them, or what data those reports relied on ^[1]. It also did not say where or in what setting Millar made the remarks.

Nor did the statement explain what Novo Nordisk means by "clinically distinct" — whether that refers to how the drugs work in the body, how they were studied, the patient groups involved, or something else ^[1]. The company did not offer an alternative comparison or say what data it considers a fair basis for judging the two treatments against each other ^[1].

It has not been reported whether the two drugs have ever been tested against each other in a single head-to-head trial. Results from separate studies are not a direct comparison, because the trials can differ in who was enrolled, how long patients were followed, and how weight loss was measured.

It also has not been reported whether the maker of orforglipron responded to Millar's statement, or whether any regulator, including the US Food and Drug Administration, has weighed in.

Why it matters for patients

People choosing among weight-management medicines increasingly see oral options discussed alongside injectables, and statements like this one shape how those choices are framed. The practical problem is that the public dispute so far rests on characterization rather than on shared numbers. Without published figures, patients and their clinicians cannot independently check the claim that one drug is more effective than the other ^[1].

Another consequence: when a manufacturer calls a comparison "misleading," that is a statement about the comparison, not a finding about either drug. The statement does not establish that the Wegovy pill works better, or that orforglipron does. It establishes only that Novo Nordisk disputes the framing ^[1].

It also has not been disclosed what evidence Novo Nordisk would accept as proof that one oral GLP-1 outperforms the other, or whether the company plans to release comparative data of its own ^[1].

What happens next

No next steps were announced alongside the statement ^[1]. No date was given for new data on either oral medicine, no timeline was offered for a possible head-to-head study, and no further comment from Novo Nordisk was scheduled.

Anything about the specific reports behind the dispute, the data they used, or a response from the maker of orforglipron has not been reported ^[1]. Patients looking for a clear answer on how the two oral drugs compare do not have one from the material released on April 1, 2026.